Spots Global Cancer Trial Database for Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
Official Title: Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma
Study ID: NCT02776813
Conditions
Study Description
Brief Summary: This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in subjects with refractory or relapsed CD20+ B-cell lymphoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Yale University, New Haven, Connecticut, United States
Loyola University Chicago, Maywood, Illinois, United States
Indiana Bone and Marrow Transplantation, Indianapolis, Indiana, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Duke University Medical Center, Durham, North Carolina, United States
Ohio State University, Columbus, Ohio, United States
Contact Details
Name: Jessica Sachs, MD
Affiliation: Cogent Biosciences, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
